-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...
The biopharmaceutical industry enters 2025 on strong footing, bolstered by scientific breakthroughs and a wave of digital innovation. In the post-AI market...
Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, announced that it has...
POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mos...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...
$25 million investment to meet growing global demand for medical devices and precision components. Expansion to quadruple manufacturing footprint for hi...
Santhera secures approximately CHF 20 million of additional funding from existing investors Highbridge and R-Bridge to accelerate global rollout Deman...
The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging...
Expanded microbiology lab and analytical chemistry capabilities position Ritedose for accelerated growth. $17+ million investment fuels innovation and...
Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an...
Kensana Health Inc. announced it has entered into a share subscription facility of up to $120 million with GEM Global Yield LLC SCS ("GEM"), a Luxembourg...
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...
NurExone Biologic Inc., a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo...
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s...
© 2025 Biopharma Boardroom. All Rights Reserved.
